TABLE 1.
Expression of surface inflammatory receptors on monocytes after stimulation of whole blood with LPS in the absence or presence of CsA, tacrolimus, or sirolimus
| Treatment | Mean specific fluorescence intensity (± SEM)a
|
||||
|---|---|---|---|---|---|
| CD14 | LFA-3 | ICAM-1 | FcγRI | HLA-DR | |
| Untreated | 54.8 ± 3.2 | 20.0 ± 4.3 | 32.5 ± 5.6 | 16.6 ± 3.6 | 53.5 ± 7.8 |
| LPS | 42.0 ± 2.0b | 21.6 ± 3.8 | 59.5 ±7.8b | 17.6 ± 4.1 | 83.3 ± 8.7b |
| LPS + CsA | 41.0 ± 2.3b | 20.0 ± 3.2 | 56.5 ± 6.5b | 19.0 ± 3.7 | 86.2 ± 11.3b |
| LPS + tacrolimus | 41.6 ± 2.3b | 19.3 ± 3.8 | 58.8 ± 8.0b | 18.6 ± 2.9 | 84.2 ± 9.6b |
| LPS + sirolimus | 42.5 ± 1.7b | 16.6 ± 5.6 | 54.8 ± 7.9b | 17.3 ±2.6 | 82.3 ± 11.7 |
a
Values are specific fluorescence intensity after appropriate gating for monocytes in whole blood treated with LPS (10 ng/ml), LPS and CsA (250 ng/ml), tacrolimus (10 ng/ml), or sirolimus (10 ng/ml).
b
Significantly different (P < 0.05) from the value for the untreated control group as calculated by analysis of variance with Tukey post hoc assessment.